Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

2.

FRET analysis reveals distinct conformations of IN tetramers in the presence of viral DNA or LEDGF/p75.

Kessl JJ, Li M, Ignatov M, Shkriabai N, Eidahl JO, Feng L, Musier-Forsyth K, Craigie R, Kvaratskhelia M.

Nucleic Acids Res. 2011 Nov 1;39(20):9009-22. doi: 10.1093/nar/gkr581. Epub 2011 Jul 19.

3.

Structure-based modeling of the functional HIV-1 intasome and its inhibition.

Krishnan L, Li X, Naraharisetty HL, Hare S, Cherepanov P, Engelman A.

Proc Natl Acad Sci U S A. 2010 Sep 7;107(36):15910-5. doi: 10.1073/pnas.1002346107. Epub 2010 Aug 23.

4.

A new functional role of HIV-1 integrase during uncoating of the viral core.

Briones MS, Chow SA.

Immunol Res. 2010 Dec;48(1-3):14-26. doi: 10.1007/s12026-010-8164-z.

PMID:
20721640
5.

Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication.

Christ F, Voet A, Marchand A, Nicolet S, Desimmie BA, Marchand D, Bardiot D, Van der Veken NJ, Van Remoortel B, Strelkov SV, De Maeyer M, Chaltin P, Debyser Z.

Nat Chem Biol. 2010 Jun;6(6):442-8. doi: 10.1038/nchembio.370. Epub 2010 May 16.

PMID:
20473303
6.

Features and development of Coot.

Emsley P, Lohkamp B, Scott WG, Cowtan K.

Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501. doi: 10.1107/S0907444910007493. Epub 2010 Mar 24.

7.

Retroviral intasome assembly and inhibition of DNA strand transfer.

Hare S, Gupta SS, Valkov E, Engelman A, Cherepanov P.

Nature. 2010 Mar 11;464(7286):232-6. doi: 10.1038/nature08784. Epub 2010 Jan 31.

8.

A novel method for determining the inhibitory potential of anti-HIV drugs.

Shen L, Rabi SA, Siliciano RF.

Trends Pharmacol Sci. 2009 Dec;30(12):610-6. doi: 10.1016/j.tips.2009.09.003. Review.

9.

Affinities between the binding partners of the HIV-1 integrase dimer-lens epithelium-derived growth factor (IN dimer-LEDGF) complex.

Tsiang M, Jones GS, Hung M, Mukund S, Han B, Liu X, Babaoglu K, Lansdon E, Chen X, Todd J, Cai T, Pagratis N, Sakowicz R, Geleziunas R.

J Biol Chem. 2009 Nov 27;284(48):33580-99. doi: 10.1074/jbc.M109.040121. Epub 2009 Sep 28.

10.

An allosteric mechanism for inhibiting HIV-1 integrase with a small molecule.

Kessl JJ, Eidahl JO, Shkriabai N, Zhao Z, McKee CJ, Hess S, Burke TR Jr, Kvaratskhelia M.

Mol Pharmacol. 2009 Oct;76(4):824-32. doi: 10.1124/mol.109.058883. Epub 2009 Jul 28.

11.

Phaser crystallographic software.

McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ.

J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674. Epub 2007 Jul 13.

12.

Structural basis for HIV-1 DNA integration in the human genome, role of the LEDGF/P75 cofactor.

Michel F, Crucifix C, Granger F, Eiler S, Mouscadet JF, Korolev S, Agapkina J, Ziganshin R, Gottikh M, Nazabal A, Emiliani S, Benarous R, Moras D, Schultz P, Ruff M.

EMBO J. 2009 Apr 8;28(7):980-91. doi: 10.1038/emboj.2009.41. Epub 2009 Feb 19.

13.

A novel co-crystal structure affords the design of gain-of-function lentiviral integrase mutants in the presence of modified PSIP1/LEDGF/p75.

Hare S, Shun MC, Gupta SS, Valkov E, Engelman A, Cherepanov P.

PLoS Pathog. 2009 Jan;5(1):e1000259. doi: 10.1371/journal.ppat.1000259. Epub 2009 Jan 9.

14.

Dynamic modulation of HIV-1 integrase structure and function by cellular lens epithelium-derived growth factor (LEDGF) protein.

McKee CJ, Kessl JJ, Shkriabai N, Dar MJ, Engelman A, Kvaratskhelia M.

J Biol Chem. 2008 Nov 14;283(46):31802-12. doi: 10.1074/jbc.M805843200. Epub 2008 Sep 18.

15.

Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs.

Shen L, Peterson S, Sedaghat AR, McMahon MA, Callender M, Zhang H, Zhou Y, Pitt E, Anderson KS, Acosta EP, Siliciano RF.

Nat Med. 2008 Jul;14(7):762-6. doi: 10.1038/nm1777. Epub 2008 Jun 15.

16.

Methods for protein characterization by mass spectrometry, thermal shift (ThermoFluor) assay, and multiangle or static light scattering.

Nettleship JE, Brown J, Groves MR, Geerlof A.

Methods Mol Biol. 2008;426:299-318. doi: 10.1007/978-1-60327-058-8_19.

PMID:
18542872
17.

Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.

Malet I, Delelis O, Valantin MA, Montes B, Soulie C, Wirden M, Tchertanov L, Peytavin G, Reynes J, Mouscadet JF, Katlama C, Calvez V, Marcelin AG.

Antimicrob Agents Chemother. 2008 Apr;52(4):1351-8. doi: 10.1128/AAC.01228-07. Epub 2008 Jan 28.

18.

Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.

Murray JM, Emery S, Kelleher AD, Law M, Chen J, Hazuda DJ, Nguyen BY, Teppler H, Cooper DA.

AIDS. 2007 Nov 12;21(17):2315-21.

PMID:
18090280
19.

Inhibiting HIV-1 integrase by shifting its oligomerization equilibrium.

Hayouka Z, Rosenbluh J, Levin A, Loya S, Lebendiker M, Veprintsev D, Kotler M, Hizi A, Loyter A, Friedler A.

Proc Natl Acad Sci U S A. 2007 May 15;104(20):8316-21. Epub 2007 May 8.

20.
Items per page

Supplemental Content

Write to the Help Desk